Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.


home / news releases / SRNE - Sorrento files for emergency use of COVI-STIX for detection of SARS-CoV-2 antigen

SRNE - Sorrento files for emergency use of COVI-STIX for detection of SARS-CoV-2 antigen

Sorrento Therapeutics Inc.
Sorrento Therapeutics (SRNE) has submitted Emergency Use Authorization ((EUA)) application to the FDA for its COVI-STIX rapid diagnostic test for the detection of SARS-CoV-2 virus nucleocapsid antigen in nasal samples of patients. In testing conducted to date, COVI-STIX has provided results within 15 minutes, with positive detection as quickly as two minutes for patient samples with high viral load.Sorrento Therapeutics may be emerging as one of the leaders in the important COVID-19 testing space, says Bull & Bear Trading in an article, "Sorrento Therapeutics May Bring Best In Class COVID-19 Tests" at Seeking Alpha.SRNE have rallied ~113% YTD, currently trading at $7.22.Shares up 7% after-hours.

For further details see:

Sorrento files for emergency use of COVI-STIX for detection of SARS-CoV-2 antigen
Stock Information
Company Name: Sorrento Therapeutics Inc.
Stock Symbol: SRNE
Market: NASDAQ
Website: sorrentotherapeutics.com
Menu
SRNE SRNE Quote SRNE Short SRNE News SRNE Articles SRNE Message Board
Get SRNE Alerts

News, Short Squeeze, Breakout and More Instantly...